CLDX - Celldex Therapeutics, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-1.00
|
Rev Est: $1.5M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$24.00
DETAILS
HIGH:
$24.00
LOW:
$24.00
MEDIAN:
$24.00
CONSENSUS:
$24.00
DOWNSIDE:
3.38%
Market Cap:
1.65B
Volume:
769,987
Avg Volume:
694,563
52 Week Range:
14.4-30.5
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.21
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
186
IPO Date:
1986-05-15
EPS (TTM):
-2.45
P/E Ratio:
-10.31
Revenue (TTM):
7.02M
Total Assets:
792.34M
Total Debt:
3.81M
Cash & Equiv:
28.36M
Rev Growth (5Y):
14.5%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-25.9%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $-1.01 | $-0.88 | -14.8% | — | $1.5M | — |
| 2025-08-07 | $-0.85 | $-0.86 | +1.2% | $730000 | $1.2M | -38.3% |
| 2025-05-08 | $-0.81 | $-0.75 | -8.0% | $695000 | $1.1M | -38.0% |
| 2025-02-27 | $-0.71 | $-0.73 | +2.7% | $1.2M | $1.3M | -6.2% |
| 2024-11-06 | $-0.64 | $-0.69 | +7.2% | $3.2M | $1.1M | +192.8% |
| 2024-08-08 | $-0.54 | $-0.59 | +8.5% | $2.5M | $820000 | +204.6% |
| 2024-05-06 | $-0.56 | $-0.67 | +16.4% | $156000 | $920000 | -83.0% |
| 2024-02-26 | $-0.57 | $-0.76 | +25.0% | $4.1M | $840000 | +391.8% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.02M | 6.88M | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M | 12.74M | 6.79M | 5.48M | 3.59M | 4.11M |
| Net Income | (157.86M) | (141.43M) | (112.33M) | (70.51M) | (59.78M) | (50.88M) | (151.18M) | (93.03M) | (128.53M) | (127.20M) | (118.08M) | (81.55M) |
| EPS | -2.45 | -2.92 | -2.40 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 |
| Total Assets | 792.34M | 465.63M | 352.74M | 444.65M | 235.84M | 122.93M | 155.81M | 315.62M | 383.36M | 337.58M | 248.01M | 347.10M |
| Total Debt | 3.81M | 2.54M | 4.03M | 3.04M | 3.48M | 3.66M | 4.53M | 6.57M | 0 | 4.42M | 2.59M | 0 |
| Cash & Equivalents | 28.36M | 34.81M | 29.43M | 39.14M | 43.84M | 11.23M | 24.31M | 40.29M | 42.46M | 72.11M | 28.02M | 169.40M |
| Operating Cash Flow | (157.78M) | (107.29M) | (103.73M) | (60.91M) | (40.40M) | (46.41M) | (75.23M) | (99.93M) | (113.04M) | (98.89M) | (101.54M) | (67.67M) |
| Free Cash Flow | (159.70M) | (109.11M) | (105.56M) | (62.16M) | (41.96M) | (47.15M) | (76.05M) | (101.72M) | (115.79M) | (103.76M) | (103.47M) | (71.89M) |
| FCF per Share | -2.48 | -2.25 | -2.25 | -1.45 | -1.42 | -3.25 | -7.28 | -11.87 | -17.11 | -16.04 | -17.36 | -13.52 |
| Book Value | 747.00M | 429.17M | 326.20M | 419.48M | 209.36M | 94.03M | 124.06M | 236.37M | 265.43M | 290.11M | 211.66M | 319.80M |
| Cash & ST Investments | 725.28M | 421.70M | 304.95M | 408.25M | 194.42M | 64.18M | 94.02M | 139.43M | 189.78M | 289.89M | 201.04M | 302.98M |
| ROC Equity | -0.21 | -0.33 | -0.34 | -0.17 | -0.29 | -0.54 | -1.22 | -0.39 | -0.48 | -0.44 | -0.56 | -0.26 |